A Personalized Chip for Precision Cancer Care

NovellusDx developed a high-throughput, gene-by-gene oncogenic activity assay, which rapidly identifies the actionable mutations within a given patient tumor. Our technology identifies tumor-specific driver mutations, based on a functional assay that detects dysregulated activation of signaling pathways. Moreover, NovellusDx assay allows examining targeted therapy drugs on a specific tumor, and quantify their therapeutic effect.

The high-throughput and combinatorial requirements of this assay necessitate miniaturization of the platform. Furthermore, its personalized nature dictates tight control over spot-to-spot contamination and high order of cell seeding density. To this end, we have developed a novel chip platform, absent of any physical boundaries, in which patient oncogenes are printed on live cells carried on a personalized chip. This platform allows for more than 2 orders of magnitude reduction in reagents volume, a considerable reduction in processing time and a significant increase in throughput.